-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

Benzinga·09/15/2026 14:16:30
语音播报
RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.